Anna-Maria Hoffmann-Vold, M.D., Ph.D., discusses the current treatment landscape for progressive pulmonary fibrosis, highlighting nonpharmacological and pharmacological options to manage the disease.

Kamilia Smith, MD, FACOG, NCMP, discusses how patient selection for novel treatments such as fezolinetant and elinzanetant must consider individual clinical characteristics, while also recognizing the unique ways that women of color may experience menopausal symptoms and barriers to care.

Anna Podolanczuk, M.D., M.S., discusses how biomarker testing plays a role in diagnosing idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), helping to distinguish these diseases from other respiratory conditions, as well as the role of biopsy and the histopathological features commonly seen in these diseases.

Kamilia Smith, MD, FACOG, NCMP, discusses how shared decision-making approaches combined with emerging neurokinin-targeted therapies offer promising solutions to improve treatment adherence and overcome historical barriers in managing vasomotor symptoms (VMS).

Anna-Maria Hoffmann-Vold, M.D., Ph.D., discusses how progressive pulmonary fibrosis is diagnosed in clinical practice, the barriers hindering early diagnosis, strategies to overcome these challenges and the critical role of early detection and intervention in improving patient outcomes and reducing long-term healthcare costs.

Anna Podolanczuk, M.D., M.S., discusses how the differential diagnosis for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) is approached, the importance of early diagnosis and why these diseases are often misdiagnosed.

Kamilia Smith, MD, FACOG, NCMP, discusses how educating patients about the serious long-term health risks of untreated vasomotor symptoms (VMS) requires a comprehensive strategy that includes clear communication about cardiovascular and cognitive consequences, alongside practical steps to improve treatment adoption and adherence.

Anna Podolanczuk, M.D., M.S., discusses how key epidemiological trends in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), including changes in incidence and prevalence, contribute to the growing economic burden that patients with these conditions face.

Kamilia Smith, MD, FACOG, NCMP, discusses how societal stigma and cultural misconceptions about menopause, combined with widespread misinformation about treatment options, create significant barriers that discourage women from seeking appropriate medical care for menopausal symptoms.